Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Ursodeoxycholic Acid Market Expected To Reach $1.59 Billion By 2030 At 10.7% CAGR
The ursodeoxycholic acid market has experienced swift expansion over recent years. It is projected to increase from $0.96 billion in 2025 to $1.06 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.0%. This growth during the historical period can be ascribed to constrained production techniques for ursodeoxycholic acid, dependence on extraction from animal sources, heightened awareness regarding liver disease management, a rise in hospital and specialist clinic treatments, and restricted research into non-alcoholic fatty liver disease.
The market for ursodeoxycholic acid is set for rapid expansion in the coming years, projected to reach $1.6 billion by 2030 with a compound annual growth rate (CAGR) of 10.7%. This forecast period growth is fueled by progress in chemical and enzymatic synthesis methods, a rising occurrence of liver and biliary conditions, the growth of specialized clinics and research centers, a greater number of regulatory approvals for synthetic UDCA, and the creation of innovative administration forms. Key trends shaping this period encompass an increasing frequency of gallstones and cholestatic liver disorders, greater uptake of synthetic and biosynthetic UDCA, the broadening of oral and intravenous delivery methods, heightened application in liver disease research and clinical trials, and a shift toward individualized therapy and dosing adjustments.
Download A Free Sample Report For Comprehensive Market Insights:
Ursodeoxycholic Acid Market Growth Drivers: What Factors Are Accelerating Expansion?
The growing incidence of liver disorders is anticipated to drive expansion in the ursodeoxycholic acid market moving forward. Liver diseases encompass a range of conditions that hinder the liver’s normal functioning, such as infections, inflammation, fatty liver, cirrhosis, and liver cancer. This increase in liver disease cases is largely attributed to higher alcohol consumption, as chronic excessive drinking can cause liver damage over time. Ursodeoxycholic acid aids in treating liver diseases by enhancing bile flow and lowering toxic bile acids, proving beneficial for conditions like primary biliary cholangitis. It improves patient outcomes by decelerating the progression of liver damage and facilitating the dissolution of cholesterol gallstones, thereby boosting overall treatment effectiveness. For example, in April 2024, data from the Office for Health Improvement and Disparities, a UK government agency, revealed 6,664 premature liver disease deaths in males and 3,929 in females, representing a 22.8% rise for males and a 33.1% increase for females compared to 2023. Consequently, the escalating prevalence of liver diseases is fueling growth in the ursodeoxycholic acid market.
The expanding elderly demographic is expected to drive the ursodeoxycholic acid market forward in the upcoming years. An aging population describes the growing share and number of older individuals within a society. This demographic shift impacts global economies, healthcare systems, and social support structures. Elderly people face a higher risk of conditions like osteoporosis, requiring early detection and prevention, highlighting the significance of bone health and its effects on medical care. Ursodeoxycholic acid is utilized among older adults to maintain liver health by managing cholestatic liver diseases and promoting bile flow. As an illustration, in January 2024, a report from the Pew Research Center, a US-based think tank, indicated that the number of centenarians was 101,000 in 2024, with projections showing an increase to 420,000 by 2054. Thus, the rising aging population is propelling the ursodeoxycholic acid market.
Ursodeoxycholic Acid Market Segment Landscape: Which Areas Lead Market Development?
The ursodeoxycholic acid market covered in this report is segmented –
1) By Type: Synthetic Ursodeoxycholic Acid, Extraction Ursodeoxycholic Acid
2) By Route Of Administration: Oral, Intravenous, Subcutaneous
3) By Application: Gallstones, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease, Other Liver And Biliary Diseases
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Research Institutions, Other End Users
Subsegments:
1) By Synthetic Ursodeoxycholic Acid: Chemically Synthesized Ursodeoxycholic Acid, Biosynthetic Ursodeoxycholic Acid, Enzymatically Synthesized Ursodeoxycholic Acid
2) By Extraction Ursodeoxycholic Acid: Animal-Derived Ursodeoxycholic Acid, Bile Extracted Ursodeoxycholic Acid, Natural Source Extracted Ursodeoxycholic Acid
Ursodeoxycholic Acid Market Trends: What Is Shaping Future Industry Growth?
Leading players in the ursodeoxycholic acid (UDCA) market are prioritizing the creation of cutting-edge treatments, including bile acid derivatives, aimed at improving management of liver conditions, especially cholestatic liver disorders. Bile acid derivatives are modified bile acid forms utilized in medical settings to boost liver function and address liver diseases. A case in point is Nora Pharma Inc., a pharmaceutical firm headquartered in Canada, which introduced a generic version of Ursodiol (ursodeoxycholic acid) in November 2024 for treating cholestatic liver diseases like primary biliary cholangitis (PBC). This drug is mainly employed to enhance liver function and decelerate the advancement of liver injury, particularly when administered at an early stage of the illness. Additionally, it works to dissolve and prevent cholesterol gallstones through altering bile composition and reducing the presence of harmful bile acids.
Ursodeoxycholic Acid Market Industry Leaders And Market Competition
Major companies operating in the ursodeoxycholic acid market are Mankind Pharma Pvt. Ltd, Abbott Healthcare Pvt. Ltd., Shandong Octagon Chemicals Limited, J.S.C. Grindeks, Arch Pharmalabs, Ind Swift Laboratories Ltd., Symbiotec Pharmalab, Suzhou Tianlu Bio-pharmaceutical Co. Ltd, Zeal MediPharma, Prodotti Chimici e Alimentari S.P.A., Mitsubishi Tanabe Pharma Corporation, ICE Pharma Inc, Xi’an Tian Guangyuan Biotech Co. Ltd, Aamorb Pharmaceuticals Inc., Axplora Inc, Octavius Pharma Pvt. Ltd, Sichuan Elixir Pharmaceutical Co. Ltd, Signova Pharma Pvt. Ltd., Sinoway Industrial Co. Ltd, Valence Labs Pvt. Ltd.
Access The Complete Ursodeoxycholic Acid Market Report:
Ursodeoxycholic Acid Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the ursodeoxycholic acid market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ursodeoxycholic acid market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model